iRemedy adds former McKesson sourcing chief to board

By AI, Created 7:06 PM UTC, May 29, 2026, /AGP/ – iRemedy Healthcare Companies has named Saul Factor, the former president of global sourcing and generics at McKesson, to its board as the company moves toward a potential NASDAQ listing. The appointment brings decades of distribution and pharmacy experience to iRemedy as it expands its AI-driven supply chain and federal procurement business.

Why it matters: - Saul Factor brings more than 30 years of experience in pharmacy, distribution and global sourcing to iRemedy’s board. - Factor’s background at McKesson and other healthcare distributors adds credibility as iRemedy pushes toward a potential public listing. - iRemedy is positioning its AI-enabled supply chain platform for lower costs and less friction in medical supply distribution.

What happened: - iRemedy Healthcare Companies appointed Saul Factor to its Board of Directors. - Factor previously served as President of Global Sourcing and Generics at McKesson Corporation, the largest pharmaceutical distributor in the United States. - At McKesson, Factor scaled the North Star generics platform from a greenfield concept to $500 million. - iRemedy said the appointment comes ahead of a potential NASDAQ listing.

The details: - Factor also held senior roles as Senior Vice President of Global Generics before becoming President of Global Sourcing at McKesson. - He later served as President of Smith Drug Company and Burlington Drug Company, wholesale distribution units of J M Smith Corporation. - Factor also led QS/1, the technology subsidiary of J M Smith Corporation. - Earlier in his career, Factor was chief operating officer of RxAmerica, LLC. - He also held leadership positions at Eli Lilly and PCS Health Systems. - Factor began his career as a retail and long-term care pharmacist. - He currently serves as an independent director of Richtech Robotics, Inc. (Nasdaq: RR). - Factor previously served as a director of McKesson Global Sourcing Ltd. - Since 2018, Factor has led Factor Healthcare Consulting, LLC, advising healthcare and pharmacy organizations on strategy, sourcing and operations. - Factor holds a Bachelor of Science in Pharmacy from Northeastern University and an MBA from the University of New Haven. - iRemedy’s current commercial focus includes distribution, specialty biologics, pharmaceutical AI and federal procurement channels. - The company recently launched TheTradeSpy.ai, an autonomous supply chain intelligence platform that now monitors more than 129,000 National Drug Codes. - iRemedy is also active in federal solicitations across multiple agencies. - Over 15 years, iRemedy says it has supplied more than 1.1 billion units of medical product to the Department of Defense, the Department of Veterans Affairs and U.S. healthcare systems. - The company says it holds 10 issued U.S. patents on AI-driven supply chain automation. - iRemedy is based in Stuart, Florida. - More information is available on iRemedy’s essential medicines page.

Between the lines: - Factor’s appointment signals iRemedy wants board-level experience in scaled distribution as it prepares for public-market scrutiny. - His public-company governance background may help the company navigate a listing process. - TheTradeSpy.ai launch and federal procurement push suggest iRemedy is trying to pair software tools with contract-driven distribution growth.

What’s next: - iRemedy is expected to keep advancing toward a possible NASDAQ listing. - The company is likely to continue expanding commercial activity across its AI, biologics and government channels. - Factor’s board role may also shape how iRemedy frames compliance, sourcing and scaling priorities as it grows.